Humanigen's stock has two lower trend resistance lines with price targets of $3 and $2, respectively.
The first resistance line has just hit after a month of major events.
Catalyst 1: Marc Bistricer of Murchison and Nomis Bay bought back in after major selling over the past year.
Catalyst 2: 7 corporate insiders including the CEO (Cameron Durrant) and Chief Scientific Officer (Dale Chappell) announced taking sizable call options at strikes between $0 and $2.85 in lieu of salary.
Catalyst 3: Bad news is out and priced in (or largely priced in). The FDA and MHRA have both informed HGEN that its applications to license lenzilumab, the company's proprietary anti-cytokine-storm therapeutic, are delayed pending further data on efficacy, safety, and manufacturing.
Catalyst 4: In December the findings from the 2020-2021 LIVE-AIR trial were published in The Lancet, one of the top 5 medical journals in the world.
Catalyst 5: the confirmatory ACTIV-5 BET trial sponsored by the NIH is now fully enrolled. The interim data readout is expected at the very earliest in late February, at the latest in early March. The FDA and MHRA will ultimately decide whether to give emergency authorization for lenzilumab as a COVID therapeutic based on the ACTIV-5 results.
The first resistance line has just hit after a month of major events.
Catalyst 1: Marc Bistricer of Murchison and Nomis Bay bought back in after major selling over the past year.
Catalyst 2: 7 corporate insiders including the CEO (Cameron Durrant) and Chief Scientific Officer (Dale Chappell) announced taking sizable call options at strikes between $0 and $2.85 in lieu of salary.
Catalyst 3: Bad news is out and priced in (or largely priced in). The FDA and MHRA have both informed HGEN that its applications to license lenzilumab, the company's proprietary anti-cytokine-storm therapeutic, are delayed pending further data on efficacy, safety, and manufacturing.
Catalyst 4: In December the findings from the 2020-2021 LIVE-AIR trial were published in The Lancet, one of the top 5 medical journals in the world.
Catalyst 5: the confirmatory ACTIV-5 BET trial sponsored by the NIH is now fully enrolled. The interim data readout is expected at the very earliest in late February, at the latest in early March. The FDA and MHRA will ultimately decide whether to give emergency authorization for lenzilumab as a COVID therapeutic based on the ACTIV-5 results.